According to Eureka Alert. a research paper published in Oncotarget a breast cancer cell that is particularly aggressive has shown that it can respond to hormone therapy. The breast cancer cell needs to have a specific type of protein that is known as estrogen receptor beta. Other molecules were also discovered that warrant further targeting, the front page article reads.
There can be a number of different types of hormone receptors in breast cancer cells. The ones that help to guide the function and growth of breast cells are either an estrogen receptor and/or a progesterone receptor. 15% of breast cancers that have been diagnosed are called triple negative breast cancer. This type of cancer is aggressive in its growth and it lacks the receptor proteins that are present in normal breast cancer cells, including progesterone and estrogen. Check Oncotarget at scimagojr.com
Oncotarget was also recently in the news for granting travel awards to four biomedical researchers. The researchers can now attend the Frontiers in Cancer Science 2017 conference that is being held this year in Singapore. The goal of Oncotarget doing these travel grants was so that the talk around cancer discoveries at this conference can be enhanced through these researchers participation. Follow Oncotarget journal on Twitter.
Oncotarget is a peer-reviewed research publication that is published every week online. It is now the biggest research publication dedicated to oncology in the world. The editor-in-chief of the publication, Mikhail Blagosklonny, said that one of his organization’s most vital missions was to expand the availability of scientific advances to that it leads to even more discoveries. Sponsoring these researchers is one way of helping meet this mission of Oncotarget’s.
The researchers include Mohd Anas Shamsi who works at the Aligarh Muslim University in India and Rajni Kumari of the National Institute of Immunology in India. The other two are Ruhi Sandeep Deshmukh, a researcher at the Molecular Oncology Laboratory for India’s National Institute of Immunology, and finally Vladan Milosevic who works in Italy at the University of Torino. The conference was held November 6th through the 8th.